 July 1, 2020 - ObsEva SA NASDAQ: OBSV SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a womans reproductive health and pregnancy, and Yuyuan BioScience Technology Yuyuan today announced that Yuyuan has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration NMPA. Nolasiban, a novel, oral oxytocin receptor antagonist, is being developed for improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization IVF. 